Home » Qiagen

Qiagen

Jan 25, 2007
Premium
Qiagen has introduced the rat druggable genome siRNA set, a collection of siRNAs targeting roughly 6,000 rat genes corresponding to human genes of therapeutic potential.
According to the company, the siRNAs are provided either individually or in pools. Subsets targeting 426 GPCR genes, 738 kinase genes, or 198 phosphatase genes are also available.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Second One From Kite

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Worth the Price?

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Beyond Counting Tree Rings

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

This Week in Nature

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.

What's Popular?

In Gene Silencing/Gene Editing

  1. Broad, DuPont Pioneer Partner to Provide Non-Exclusive Licenses to CRISPR IP

  2. Majority of Genetics Professionals Supports Human Gene Editing, Stanford Survey Finds

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.